Research & Development研究開発

3つのパイプラインが日米で臨床試験進行中
3 pipelines are ongoing clinical study in Japan & USA

Main Pipeline Population Basic
research
Pre-
clinical
Phase I Phase II Phase III NDA/
Approval
DFP-10917 AML 2021
(Schedule)
DFP-14323 NSCLC
(Stage III/IV)
DFP-11207 Pancreatic
cancer
← Food effect study
DFP-14927 Solid tumor

DFP-10825 Peritoneal disseminated OC, GC

パイプラインの特許を主要国で取得
Patent is granted by major countries

Pipelines Category Granted Countries
DFP-10917 Substance Japan, USA, EU, Russia, Australia, China and South Korea
DFP-11207 Substance Japan, USA, EU, Russia, Australia, China and South Korea
DFP-14323 Substance and use Japan and Taiwan (Exam. in US, EU, China, etc.)
DFP-10825 Substance Japan, USA, EU, Russia, Australia, China and South Korea
DFP-14927 Substance (Examination in Japan, US, EU, China, etc.)
DFP-17729 Substance and use (PCT and Taiwan application)

がん化学療法専門誌、専門学会における活動
Publication of Professional Journal and Conference

DFP-10917

Conference
American Society of Hematology
58th Annual Meeting & Exposition San Diego, CA /December 2016
Title
Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study
Presenter
H. Kantarjian, E. Jabbour, G. Garcia-Manero, T. Kadia, C. Dinardo, N. Daver, G. Borthakur, N. Jain, J. Waukau, M. Kwari, F. Ravandi, B. Anderson, K. Iizuka, C. Jin, C. Zhang, W. Plunkett
Journal
International of Oncology January 16, 2018
Title
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Author
Kenzo Iizuka, Chun Zhang, Kokoro Eshima, Cheng Jin, Kiyoshi Eshima, Masakazu Fukushima

DFP-11207

Journal
Drug Design, Development and Therapy 2017:11 1693–1705
Title
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents
Author
Masakazu Fukushima, Kenzo Iizuka, Cheng Jin, Chun Zhang, Mei Hong, Kiyoshi Eshima

DFP-10825

Journal
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 355-363, 2011
Title
Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Author
KYUICHI KADOTA, CHENG-LONG HUANG, DAGE LIU, HIROYASU YOKOMISE, REIJI HABA and HIROMI WADA
Journal
Molecular Pharmaceutics 2016, 13, 3955−3963
Title
Systemically Administered RNAi Molecule Sensitizes Malignant Pleural Mesotheliomal Cells to Pemetrexed Therapy
Author
Amr S. Abu Lila, Masakazu Fukushima, Cheng-Long Huang, Hiromi Wada, and Tatsuhiro Ishida
Journal
Cancer Letters 400 (2017) 223-231
Title
Metronomic S-1 Dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model
Author
Amr S. Abu Lila, Naoto Moriyoshi, Masakazu Fukushima, Cheng-Long Huang, Hiromi Wada and Tatsuhiro Ishida
Journal
INTERNATIONAL JOURNAL OF ONCOLOGY 48: 1399-1407, 2016
Title
Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model
Author
AMR S ABU LILA, CHIHIRO KATO, MASAKAZU FUKUSHIMA, CHENG-LONG HUANG, HIROMI WADA and TATSUHIRO ISHIDA

DFP-17729

Journal
ANTICANCER RESEARCH 37: 5141-5145 (2017)
Title
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC
Author
REO HAMAGUCHI, TOSHIHIRO OKAMOTO, MASAAKI SATO, MICHIKO HASEGAWA and HIROMI WADA